Listed by the USPTO as ROGERS, JAMES WILLIAM
Tech Center 1600 • Art Units: 1618
This examiner grants 46% of resolved cases
ROGERS, JAMES WILLIAM handles cases in tech center 1600 and art unit 1618. The profile contains 906 resolved cases, with a 46.1% allowance rate and a median of 1407 days to allowance. The 22.4% interview lift provides a measurable reason to include interview preparation in prosecution planning.
The principal listed companies are Nivagen Pharmaceuticals Inc., Rutgers, The State University of New Jersey, and University of Massachusetts. The listed firms are Barnes & Thornburg LLP (IN), Knobbe, Martens, Olson & Bear, LLP, and BIRCH STEWART KOLASCH & BIRCH, LLP. Applicants should account for the allowance result and extended median timing when setting expectations for claim development and prosecution duration.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18208672 | PROTEIN-TEMPLATED SELF-ASSEMBLY OF A COVALENT POLYMER NETWORK FOR INTRACELLULAR TRAFFICKING AND TRACELESS RELEASE | Final Rejection | University of Massachusetts |
| 18552760 | DIAGNOSTIC METHODS OF PROSTATE CANCER | Non-Final OA | NOVARTIS AG |
| 17771142 | POLYMERIC NANOPARTICLES FOR INTRACELLULAR PROTEIN DELIVERY | Final Rejection | The Johns Hopkins University |
| 18548724 | A DELTA-OPIOID RECEPTOR TARGETED AGENT FOR MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER | Non-Final OA | WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY |
| 18038555 | RADIATION-ACTIVATED TETRAVALENT PLATINUM COMPLEX AND USE THEREOF | Final Rejection | PEKING UNIVERSITY |
| 18560675 | FOLATE RECEPTOR-TARGETED CONJUGATES WITH BRUSH BORDER MEMBRANE ENZYME-CLEAVABLE LINKERS AND METHODS OF USE IN IMAGING AND TREATING CANCER | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 17064352 | INORGANIC NANOCAGES, AND METHODS OF MAKING AND USING SAME | Non-Final OA | Cornell University |
| 18566935 | BENCH-STABLE TRIAZENE COMPOSITIONS FOR PROTEIN MODIFICATION | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17997908 | POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION AND METHOD FOR DETECTION OF BACTERIAL INFECTION | Final Rejection | The Research Foundation for the State University of New York |
| 18561702 | MAGNETIC NANOPARTICLES FOR IMAGE DIAGNOSIS AND CONTRAST MEDIUM FOR IMAGE DIAGNOSIS | Non-Final OA | OSAKA UNIVERSITY |
| 17726296 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
| 18552124 | [161Tb]-BASED RADIOPEPTIDES | Non-Final OA | PAUL SCHERRER INSTITUT |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.1% of resolved applications examined by James William Rogers were allowed (906 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +22.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by James William Rogers took 1,407 days on average from filing to allowance.
James William Rogers examines applications in Art Unit 1618 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
